Newfound biomarkers may someday help clinicians better detect—and possibly cure—Lyme disease

Lyme disease can be easiest to treat in its earliest stages, but current tests often miss infections during that critical window and cannot tell whether bacteria are still present or were cleared years ago.

New research led by Tufts University School of Medicine suggests that a group of immune molecules called anti-lipid antibodies may address these shortcomings. ...